The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study

  • Azoulay L
  • Hui Y
  • Filion K
 et al. 
  • 1

    Readers

    Mendeley users who have this article in their library.
  • N/A

    Citations

    Citations of this article.

Abstract

research; tables/charts. Commentary: Hillaire-Buys Dominique,
Faillie Jean-Luc. Pioglitazone and the risk of bladder cancer:
Risks seem to outweigh benefits as yet more evidence emerges.
(BMJ BR MED J (OVERSEAS & RETIRED DOCTORS ED)) 6/23/2012; 344
(7862): 7-7. Journal Subset: Biomedical; Blind Peer Reviewed;
Editorial Board Reviewed; Europe; Expert Peer Reviewed; Peer
Reviewed; UK & Ireland. Special Interest: Oncologic Care.
Grant Information: This study was supported by grants from the
Canadian Institutes of Health Research and the Canadian
Foundation for Innovation.. NLM UID: 101090866.

Author-supplied keywords

  • Bladder Neoplasms -- Risk Factors Diabetes Mellitu
  • Type 2 -- Epidemiology Pioglitazone -- Adverse Ef

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

There are no full text links

Authors

  • Laurent Azoulay

  • Yin Hui

  • Kristian B Filion

  • Jonathan Assayag

  • Agnieszka Majdan

  • Michael N Pollak

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free